26.47
+0.845(+3.30%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
113
First IPO Date
N/A
| Name | Title | Pay | Year Born |
| Mr. Arthur Kuan | Chairman & Chief Executive Officer | 1.04M | 1991 |
| Dr. Vijay Kasturi M.D. | Chief Medical Officer | 299,688 | 1968 |
| Ms. Corleen M. Roche | Chief Financial Officer | 687,827 | 1967 |
| Mr. Ambaw Bellete M.S. | President & Chief Operating Officer | 769,967 | 1971 |
| Ms. Sarah Connors | Vice President of Communications & Patient Advocacy | 0 | N/A |
| Mr. Joshua F. Patterson | General Counsel, Chief Compliance Officer & Secretary | 0 | 1977 |
| Mr. Swapnil Bhargava Ph.D. | Chief Technical Officer | 0 | N/A |
| Ms. Amy Steele | Vice President of Finance, Accounting & Administration | 0 | N/A |
| Mr. Bing Kung | Vice President of Corporate Development | 0 | N/A |
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.